DUBLIN--(BUSINESS WIRE)--The "Psoriatic Arthritis Treatment Market Forecast - Epidemiology & Pipeline Analysis 2022-2027" report has been added to ResearchAndMarkets.com's offering.
The global psoriatic arthritis treatment market is expected to grow at a CAGR of 8.09% during 2022-2027.
Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory rheumatic disease characterized by pain, stiffness, swollen joints, joint erosion, and bone formation. Psoriatic arthritis occurs in up to 30% of patients with psoriasis, most commonly those aged between 30 and 60 years. It starts about 10 years after psoriasis develops for many people, but some develop PsA first or without ever developing or noticing psoriasis.
PsA can occur at any age and affects men and women equally. In recent years, women have contributed more to the global psoriatic arthritis treatment market as they are at greater risk of developing psoriatic arthritis. According to estimates, in the European Union, PsA affects more than 2 million people, and in the United States, about 0.5 million.
The exact cause of PsA is not yet known. Family history plays a strong role; about 40% of those with the disease have a family member with psoriasis or arthritis. Risk factors can include obesity, severe psoriasis, nail disease, and trauma or deep lesions at sites of trauma.
Key Highlights
The psoriatic arthritis treatment market portfolio contains a total of 25+ assets that are in various phases of development. Most industry-sponsored drugs in active clinical development for psoriatic arthritis are in the Phase III stage. The emerging therapeutics for psoriatic arthritis include Bimekizumab, Tildrakizumab, SHR-0302, Neihulizumab, and many others.
Launching these novel emerging drugs will shift the PsA treatment paradigm in the near future. With more than 25 molecules in various stages of development, it is expected that new vendors are likely to enter the industry with a novel mechanism of action and better safety and efficacy profiles compared to the existing patented commercial drugs for treating psoriatic arthritis.
Psoriatic Arthritis: Clinical Trials Scenario
The clinical trial portfolio contains 150+ trials in various development phases. Most industry-sponsored drugs in active clinical development for PsA are in the Phase III stage. The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for psoriatic arthritis have been in the late phase of development, with 58% of trials in Phase II/III & III and only 41% in Phase Phase I-II.
Market Drivers and Trends
Increasing Adoption of Biological Therapies
Biological therapies such as anti-tumor necrosis factor (TNF) and anti-interleukin antibodies are widely used in the psoriatic arthritis treatment market. With Stelara being biologic approved for PsA in 2013, there is a demand for therapies with novel MOAs that are less immunogenic than current offerings.
Many new classes of therapies are looking to enter the psoriatic arthritis treatment market over the next few years. The biologics such as interleukin inhibitors are making inroads into the psoriatic arthritis market owing to better clinical profile and convenient patient dosing.
Focus on Novel Drugs with Novel Mechanism
Over the past seven years, agents that block inflammatory pathways other than tumor necrosis factor (TNF) represent new options for treating psoriasis arthritis (PsA). The therapeutic agents targeting the IL-23/IL-17 axis have been proven to be very effective in psoriatic arthritis, some are already in the therapeutic armamentarium, and others are in development. IL-23/IL-17 axis cytokines are essential players in the pathogenesis of psoriasis and PsA.
Key Vendors
- AbbVie Inc.
- Johnson & Johnson
- UCB SA
- Amgen
- Bristol-Myers Squibb
- Pfizer
- Eli Lilly and Company
- Novartis
Other Prominent Vendors
- Samsung Bioepis
- Boehringer Ingelheim
- Mylan
- Merck & Co., Inc
- Coherus BioSciences, Inc
Key Emerging Vendors with Late Stage Pipeline Drugs
- Sun Pharmaceuticals
- Bausch Health Companies Inc
- Jiangsu HengRui Medicine Co. Ltd
- Biocad Biopharmaceutical
- Meiji Holdings Co Ltd
- Bio-Thera
Market Segmentation
by Drug Class
- TNF Inhibitors
- Interleukin Inhibitors
- NSAIDs
- Other classes of Drugs
- Gender Type: Women accounted for a significant share of the global psoriatic arthritis treatment market under the gender type segment. This is because women have been at greater risk of psoriatic arthritis in recent years.
by Gender Type
- Men
- Women
- Disease Type: Enthesitis is expected to account for a significant share. However, Dactylitis is expected to be the fastest growing segment during the forecast period.
by Disease Type
- Spondylitis
- Enthesitis
- Dactylitis
- Age Group: People aged 50 years and below are expected to account for a significant share of the global psoriatic arthritis treatment market.
by Age Group
- 50 years and Below
- 50 years and Above
- Severity Type: People with mild form are expected to account for a significant share of the global psoriatic arthritis treatment market under the severity type category. However, people with moderate form are expected to be the fastest growing segment during the forecast period.
by Severity Type
- Moderate
- Mild
- Severe
by Geography
- North America
- United States
- APAC
- China
- Japan
- Europe
- U.K.
- France
- German
- Italy
- Spain
Key Questions Answered:
1. How big is the global psoriatic arthritis treatment market?
2. What is the growth rate of the global psoriatic arthritis treatment market?
3. What factors drive the growth of the psoriatic arthritis treatment market?
4. Who are the leading vendors operating in the psoriatic arthritis treatment market?
5. Which region holds the largest share in the global psoriatic arthritis treatment market?
For more information about this report visit https://www.researchandmarkets.com/r/x94ylx
